Physician profile
Alexander Beyzer
NPI 1063526093
$10,964.39
in general payments reported to CMS, 2019-2025
39 companies · $2,381 in 2025
The $2,381 reported for 2025 was more than what 83% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,195 · 2020: $683 · 2021: $1,035 · 2022: $555 · 2023: $1,353 · 2024: $2,762 · 2025: $2,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,697 · Honoraria: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,696.75 |
| Honoraria | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,913.49 | 2019-2025 | Relistor, Xifaxan |
| Protega Pharmaceutials INC | $2,411.53 | 2024-2025 | Roxybond |
| Collegium Pharmaceutical, INC. | $1,386.86 | 2019-2025 | Belbuca, Xtampza |
| Biodelivery Sciences International, INC. | $739.82 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $359.63 | 2019-2024 | Uzedy, Austedo Xr |
| Scilex Pharmaceuticals INC. | $276.43 | 2019-2023 | Ztlido |
| Mdd US Operations, LLC | $255.32 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $255.11 | 2019 | |
| Arbor Pharmaceuticals, INC. | $234.59 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $228.42 | 2024-2025 | Nuplazid |
| Curonix LLC | $216.37 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Valinor Pharma, LLC | $210.06 | 2023-2025 | Movantik |
| Bioventus LLC | $208.76 | 2021 | |
| Horizon Therapeutics Plc | $167.17 | 2019-2020 | |
| Daiichi Sankyo INC. | $162.06 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $120.37 | 2023 | Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $114.65 | 2021 | |
| Alkermes, INC. | $100.63 | 2025 | Lybalvi |
| Averitas Pharma INC. | $94.50 | 2023 | Qutenza |
| Vanda Pharmaceuticals INC. | $86.86 | 2025 | Fanapt |
| Astrazeneca Pharmaceuticals Lp | $49.52 | 2019-2020 | |
| Kaleo, INC. | $37.80 | 2019 | |
| Pfizer INC. | $34.01 | 2021-2024 | |
| Redhill Biopharma INC. | $32.80 | 2022-2023 | |
| Assertio Therapeutics, INC. | $31.66 | 2019-2020 | |
| Ibsa Pharma INC. | $31.31 | 2022-2023 | Tirosint, Licart |
| Virtus Pharmaceuticals LLC | $29.40 | 2021 | |
| Forte Bio-Pharma LLC | $24.64 | 2022 | |
| Currax Pharmaceuticals LLC | $22.78 | 2019-2020 | |
| Medtronic USA, INC. | $22.04 | 2020 | |
| Amgen INC. | $19.49 | 2022 | |
| Fidia Pharma USA INC. | $16.68 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.15 | 2025 | |
| Vertical Pharmaceuticals, LLC | $14.35 | 2019 | |
| Azurity Pharmaceuticals, INC. | $13.68 | 2024 | Horizant |
| Kowa Pharmaceuticals America, INC. | $13.35 | 2023 | Seglentis |
| Tersera Therapeutics LLC | $13.10 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Beyzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.